35874059|t|Anti-inflammatory effects of Torin2 on lipopolysaccharide-treated RAW264.7 murine macrophages and potential mechanisms.
35874059|a|Context: Torin2 has various pharmacological properties. However, its anti-inflammatory activity has not been reported. Objective: This study focused on the potential anti-inflammatory properties of Torin2 in lipopolysaccharide (LPS)-evoked RAW264.7 murine macrophages. The study aimed to shed light on the molecular mechanisms that ameliorate these effects. Methods: Torin2 was applied to 100 ng/mL lipopolysaccharide-induced RAW 264.7 macrophages in vitro. Nitric oxide (NO) levels were detected using the Griess reagent kit. Prostaglandin E2 (PGE2), pro-inflammatory cytokines interleukin (IL)-1beta, interleukin (IL)-6, and tumor necrosis factor in the supernatant fraction were determined using enzyme-linked immunosorbent assay (ELISA). Gene expression of pro-inflammatory cytokines, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) were tested using real-time quantitative polymerase chain reaction (qPCR). Cyclooxygenase-2 and inducible nitric oxide synthase proteins, phosphorylation of mitogen-activated protein kinase (MAPK) subgroups, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38, I-kappa-B-alpha (IkappaBalpha), and nuclear factor-kappa-B (NF-kappaB), and activation in extracts were detected via western blotting. Nuclear factor-kappa-B/p65 nuclear translocation was tested using an immunofluorescence assay. Results: The results demonstrated that pre-treatment with Torin2 profoundly attenuated the lipopolysaccharide-stimulated levels of nitric oxide and prostaglandin E2, pro-inflammatory cytokines, messenger ribonucleic acid (mRNA), and protein expression of cyclooxygenase-2 and inducible nitric oxide synthase. Collectively, Torin2 pre-treatment notably weakened lipopolysaccharide-induced damage by reducing the phosphorylation of nuclear factor-kappa-B, p38, c-Jun N-terminal kinase, extracellular signal-regulated kinase proteins, and nuclear factor-kappa-B/p65 nuclear translocation. Conclusion: Numerous pieces of evidence indicated that Torin2 reversed inflammatory activation by regulating nuclear factor-kappa-B and mitogen-activated protein kinase signaling pathways and provided a tentative potential candidate for preventing and treating inflammatory diseases.
35874059	5	17	inflammatory	Disease	MESH:D007249
35874059	29	35	Torin2	Chemical	-
35874059	39	57	lipopolysaccharide	Chemical	MESH:D008070
35874059	66	74	RAW264.7	CellLine	CVCL:0493
35874059	75	81	murine	Species	10090
35874059	194	206	inflammatory	Disease	MESH:D007249
35874059	291	303	inflammatory	Disease	MESH:D007249
35874059	318	324	Torin2	Chemical	-
35874059	328	346	lipopolysaccharide	Chemical	MESH:D008070
35874059	348	351	LPS	Chemical	MESH:D008070
35874059	360	368	RAW264.7	CellLine	CVCL:0493
35874059	369	375	murine	Species	10090
35874059	487	493	Torin2	Chemical	-
35874059	519	537	lipopolysaccharide	Chemical	MESH:D008070
35874059	546	555	RAW 264.7	CellLine	CVCL:0493
35874059	578	590	Nitric oxide	Chemical	MESH:D009569
35874059	647	663	Prostaglandin E2	Chemical	MESH:D015232
35874059	665	669	PGE2	Chemical	MESH:D015232
35874059	676	688	inflammatory	Disease	MESH:D007249
35874059	699	721	interleukin (IL)-1beta	Gene	16176
35874059	723	741	interleukin (IL)-6	Gene	16193
35874059	747	768	tumor necrosis factor	Gene	21926
35874059	885	897	inflammatory	Disease	MESH:D007249
35874059	909	925	cyclooxygenase-2	Gene	19225
35874059	927	932	COX-2	Gene	19225
35874059	939	970	inducible nitric oxide synthase	Gene	18126
35874059	972	976	iNOS	Gene	18126
35874059	1053	1069	Cyclooxygenase-2	Gene	19225
35874059	1074	1105	inducible nitric oxide synthase	Gene	18126
35874059	1186	1223	extracellular signal-regulated kinase	Gene	26413
35874059	1225	1228	ERK	Gene	26413
35874059	1231	1254	c-Jun N-terminal kinase	Gene	26419
35874059	1256	1259	JNK	Gene	26419
35874059	1262	1265	p38	Gene	26416
35874059	1267	1282	I-kappa-B-alpha	Gene	18035
35874059	1284	1296	IkappaBalpha	Gene	18035
35874059	1303	1325	nuclear factor-kappa-B	Gene	18033
35874059	1327	1336	NF-kappaB	Gene	18033
35874059	1402	1424	Nuclear factor-kappa-B	Gene	18033
35874059	1425	1428	p65	Gene	19697
35874059	1555	1561	Torin2	Chemical	-
35874059	1588	1606	lipopolysaccharide	Chemical	MESH:D008070
35874059	1628	1640	nitric oxide	Chemical	MESH:D009569
35874059	1645	1661	prostaglandin E2	Chemical	MESH:D015232
35874059	1667	1679	inflammatory	Disease	MESH:D007249
35874059	1752	1768	cyclooxygenase-2	Gene	19225
35874059	1773	1804	inducible nitric oxide synthase	Gene	18126
35874059	1820	1826	Torin2	Chemical	-
35874059	1858	1876	lipopolysaccharide	Chemical	MESH:D008070
35874059	1927	1949	nuclear factor-kappa-B	Gene	18033
35874059	1951	1954	p38	Gene	26416
35874059	1956	1979	c-Jun N-terminal kinase	Gene	26419
35874059	1981	2018	extracellular signal-regulated kinase	Gene	26413
35874059	2033	2055	nuclear factor-kappa-B	Gene	18033
35874059	2056	2059	p65	Gene	19697
35874059	2154	2166	inflammatory	Disease	MESH:D007249
35874059	2192	2214	nuclear factor-kappa-B	Gene	18033
35874059	2344	2365	inflammatory diseases	Disease	MESH:D007249
35874059	Association	MESH:D007249	16193
35874059	Positive_Correlation	MESH:D008070	MESH:D015232
35874059	Positive_Correlation	MESH:D008070	MESH:D007249
35874059	Positive_Correlation	MESH:D008070	19225
35874059	Association	MESH:D008070	26413
35874059	Association	MESH:D008070	26416
35874059	Positive_Correlation	MESH:D008070	18126
35874059	Association	MESH:D008070	18033
35874059	Association	MESH:D008070	19697
35874059	Association	MESH:D008070	26419
35874059	Positive_Correlation	MESH:D008070	MESH:D009569

